Guardant360

Guides therapeutic decision-
making in
18 days vs 31 days
with tissue testing.1,2*

  • Covers an expanded
    panel of biomarkers,
    including bTMB, MSI
    status, HRR gene set, and
    NTRK fusions.3,5-7

  • Results in
    10 days.*

  • Medicare coverage
    for all advanced
    solid tumors.†

An expanded panel of biomarkers

The expanded panel includes bTMB, MSI status, expanded HRR gene set, and full coverage of NTRK fusions.3,5-7

Guardant360 Panel3,5,7Guardant360 Panel3,5,7
AKT1FGFR2NOTCH1
ALKFGFR3NPM1
APCGATA3NRAS
ARGNA11NTRK1
ARAFGNAQNTRK2
ARID1AGNASNTRK3
ATMHNF1APALB2
BRAFHRASPDGFRA
BRCA1IDH1PIK3CA
BRCA2IDH2PMS2
CCND1JAK2PTEN
CCND2JAK3PTPN11
CCNE1KEAP1RAD51D
CDH1KITRAF1
CDK12KRASRB1
CDK4MAP2K1RET
CDK6MAP2K2RHEB
CDKN2AMAPK1RHOA
CHEK2MAPK3RIT1
CTNNB1METROS1
DDR2MLH1SMAD4
EGFRMPLSMO
ERBB2MSH2STK11
ESR1MSH6TERT
EZH2MTORTP53
FANCAMYCTSC1
FBXW7NF1VHL
FGFR1NFE2L2
AKT1CCND1DDR2GATA3KEAP1MSH2NTRK2RB1TP53
ALKCCND2EGFRGNA11KITMSH6NTRK3RETTSC1
APCCCNE1ERBB2GNAQKRASMTORPALB2RHEBVHL
ARCDH1ESR1GNASMAP2K1MYCPDGFRARHOA
ARAFCDK12EZH2HNF1AMAP2K2NF1PIK3CARIT1
ARID1ACDK4FANCAHRASMAPK1NFE2L2PMS2ROS1
ATMCDK6FBXW7IDH1MAPK3NOTCH1PTENSMAD4
BRAFCDKN2AFGFR1IDH2METNPM1PTPN11SMO
BRCA1CHEK2FGFR2JAK2MLH1NRASRAD51DSTK11
BRCA2CTNNB1FGFR3JAK3MPLNTRK1RAF1TERT

Liquid CGP testing provides guideline-complete genotyping more often than tissue-only testing.1

Resulted in guideline-complete genotyping in 95% of patients, compared with 18% in patients with tissue genotyping alone (n=268 for ctDNA arm; n=51 for tissue arm).1

Get results faster so patients can start treatment sooner.

  • vs

Patients testing with Guardant360® started targeted therapy
approximately 18 days following the initiation of testing, compared with 31 days for those who underwent tissue biopsies. All patients responded to targeted therapy similarly regardless of biopsy type.2

Treatment response results are comparable between liquid CGP testing and tissue testing.8

PFS rates in patients receiving targeted therapy,
based on results from tissue vs ctDNA testing8

NON-SMALL CELL LUNG CANCER (NSCLC) DATA

Identify more actionable biomarkers to inform treatment selection.4

  • Guardant360® in combination with
    tissue biopsy identified nearly 2X more patients with targeted biomarkers
    versus tissue biopsy alone.4

NSCLC patients with targeted mutations detected by testing modality9

Tissue alone47
Tissue + Guardant36082
Tissue alone47
Tissue + Guardant36082

  • In rescue cases of QNS, 44% of tissue biopsy patients were unable to get results from tissue alone.9

Guardant360

Get results in as little as 10 days.

Order a kit

References: 1. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691-4700. doi:10.1158/1078-0432.CCR-19-0624 2. Page RD, Drusbosky LM, Dada H, et al. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer. Clin Lung Cancer. 2022;23(1):72-81. doi:10.1016/j.cllc.2021.10.001 3. Guardant360® Assay Specifications. Guardant Health, Inc. Redwood City, CA. 4. Cui W, Milner-Watts C, O'Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 5. National Institutes of Health. Guardant360. National Library of Medicine; Bethesda, MD. Updated August 12, 2021. Accessed June 29, 2023. https://www.ncbi.nlm.nih.gov/gtr/tests/527948. 6. Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2:1-13. doi:10.1200/PO.17.00286 7. Guardant360® Gene Pocket Guide. Guardant Health, Inc. Redwood City, CA. 8. Palmero R, Taus A, Viteri S, et al. Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer. JCO Precis Oncol. 2021;5:93-102. doi:10.1200/PO.20.00241 9. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic nonsmall cell lung cancer. JAMA Oncol. 2019;5(2):173-180. doi:10.1001/jamaoncol.2018.4305 10. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021.